Format

Send to

Choose Destination
Sci Transl Med. 2019 Jan 23;11(476). pii: eaar4289. doi: 10.1126/scitranslmed.aar4289.

Rapamycin and Alzheimer's disease: Time for a clinical trial?

Author information

1
Department of Pathology, University of Washington, Seattle, WA 98045, USA. kaeber@uw.edu galvanv@uthscsa.edu.
2
Department of Cellular and Integrative Physiology, Barshop Institute for Longevity and Aging Studies and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, TX 78229, USA. kaeber@uw.edu galvanv@uthscsa.edu.
3
Department of Veterans Affairs, South Texas Veterans Health Care System and Geriatric Research Education and Clinical Center, San Antonio, TX 78229, USA.

Abstract

The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center